Literature DB >> 17883289

Lapatinib.

Sohita Dhillon1, Antona J Wagstaff.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17883289     DOI： 10.2165/00003495-200767140-00008

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  19 in total

1.  The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Authors:  D W Rusnak; K Lackey; K Affleck; E R Wood; K J Alligood; N Rhodes; B R Keith; D M Murray; W B Knight; R J Mullin; T M Gilmer
Journal:  Mol Cancer Ther       Date:  2001-12       Impact factor: 6.261

2.  Targeting HER2 in brain metastases from breast cancer.

Authors:  David G Kirsch; Fred H Hochberg
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

Review 3.  Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.

Authors:  Filippo Montemurro; Giorgio Valabrega; Massimo Aglietta
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

4.  Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Authors:  Howard A Burris; Herbert I Hurwitz; E Claire Dees; Afshin Dowlati; Kimberly L Blackwell; Bert O'Neil; Paul K Marcom; Matthew J Ellis; Beth Overmoyer; Suzanne F Jones; Jennifer L Harris; Deborah A Smith; Kevin M Koch; Andrew Stead; Steve Mangum; Neil L Spector
Journal:  J Clin Oncol       Date:  2005-06-13       Impact factor: 44.544

5.  ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC).

Authors:  V V Kataja; M Colleoni; J Bergh
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

6.  The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

Authors:  Isabel Chu; Kimberly Blackwell; Susie Chen; Joyce Slingerland
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

7.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

Authors:  Gottfried E Konecny; Mark D Pegram; Natarajan Venkatesan; Richard Finn; Guorong Yang; Martina Rahmeh; Michael Untch; David W Rusnak; Glenn Spehar; Robert J Mullin; Barry R Keith; Tona M Gilmer; Mark Berger; Karl C Podratz; Dennis J Slamon
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

8.  Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

Authors:  Rita Nahta; Linda X H Yuan; Yi Du; Francisco J Esteva
Journal:  Mol Cancer Ther       Date:  2007-02       Impact factor: 6.261

9.  Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

Authors:  Wenle Xia; Intisar Husain; Leihua Liu; Sarah Bacus; Shermini Saini; Janice Spohn; Karen Pry; Ron Westlund; Steven H Stein; Neil L Spector
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701
View more
  9 in total

Review 1.  Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.

Authors:  Monique P Curran
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

2.  Treatment of vestibular schwannoma cells with ErbB inhibitors.

Authors:  Matthew L Bush; Sarah S Burns; Janet Oblinger; Sholpan Davletova; Long-Sheng Chang; D Bradley Welling; Abraham Jacob
Journal:  Otol Neurotol       Date:  2012-02       Impact factor: 2.311

3.  ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

Authors:  Sylwia Ammoun; Clare H Cunliffe; Jeffrey C Allen; Luis Chiriboga; Filippo G Giancotti; David Zagzag; C Oliver Hanemann; Matthias A Karajannis
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

4.  Extended transit compartment model to describe tumor delay using Coxian distribution.

Authors:  Jong Hyuk Byun; In-Soo Yoon; Song Yi Lee; Hyun-Jong Cho; Il Hyo Jung
Journal:  Sci Rep       Date:  2022-06-16       Impact factor: 4.996

5.  Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2012-07-27       Impact factor: 12.300

Review 6.  Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2009-10-22       Impact factor: 9.546

7.  Tailored targeted therapy for all: a realistic and worthwhile objective?

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

8.  Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.

Authors:  Eugene R Ahn; Emilie Wang; Stefan Glück
Journal:  Breast Cancer (Auckl)       Date:  2012-11-19

9.  Synthesis, Biological Evaluation and Docking Analysis of Some Novel Quinazolin Derivatives as Antitumor Agents.

Authors:  Walaa S El-Serwy; Neama A Mohamed; Emad M M Kassem; Khaled Mahmoud; M M Mounier
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.